FOA Title: 

RESCINDED - Notice of Intent to Publish a Funding Opportunity Announcement for Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3)

Grant Type: 

NOT-HL-18-620

Primary IC: 

NHLBI

Release Date: 

Apr 13 2018

Expiration Date: 

N/A

AC Source: 

N/A

Purpose: 

Notice Intent Publish Funding Opportunity Announcement Rare Disease Cohorts Heart, Lung, Blood Sleep Disorders UG3/UH3) Notice Number: NOT-HL-18-620 Key Dates Release Date: April 13, 2018 RESCINDED) Estimated Publication Date Funding Opportunity Announcement: 12/01/2018 First Estimated Application Due Date:02/01/2019 Earliest Estimated Award Date:10/31/2019 Earliest Estimated Start Date:12/31/2019 Related Announcements None Issued National Heart, Lung, Blood Institute NHLBI) Purpose National Heart, Lung Blood Institute intends promote new initiative establish cohorts rare heart, lung, blood, and/or sleep HLBS) diseases enables multidisciplinary teams conduct natural history mechanistic studies provide evidence base future clinical trials improved diagnostics.  studies help advance fundamental insights key molecular, genomic, clinical, environmental behavioral determinants rare HLBS diseases their outcomes leading diagnostic therapeutic strategies.   NHLBI interested applications will address questions relevant the NHLBI mission, address gaps the NHLBI?s portfolio rare disease cohorts that align the Institute ' s Strategic Vision https://www.nhlbi.nih.gov/about/documents/strategic-vision). NHLBI intends to utilize UG3/UH3 activity code, bi-phasic, milestone-driven cooperative agreement. Details the planned FOA provided below. Notice being provided allow potential applicants sufficient time develop responsive proposals.  FOA expected be published October 2018 anticipated application receipt dates February 2019 February 2020. Research Initiative Details planned initiative provide opportunities efficiently advance rare disease research using genetics deep phenotyping characterize disease to identify disease sub-types; use data science methods integrate clinical patient-reported outcomes PROs) laboratory, imaging omics data understand natural history disease;  generate data differentiate patients the same morphological phenotype different genetic mutations  severity outcomes; elucidate genotype-phenotype interactions multisystem phenotyping develop reliable valid predictive tools determine will respond which treatments when intervene; to encourage innovative methods such telemedicine reach subjects rare diseases located remote locations without access a major academic medical center. goal this initiative to encourage creative innovative research; such, applications should propose studies investigating hypotheses research questions currently addressed cohorts funding the NHLBI. RFA invite applications propose cohorts are created de novo or re-establish study populations enrolling patients previously-funded cohorts, clinical trials registries. Funding Information Estimated Total Funding 1,625,000 Total Costs) Expected Number Awards 4 Estimated Award Ceiling 500,000 Direct Costs) Primary CFDA Numbers 93.837, 93.838, 93.839, 93.840, 93.233 Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Nonprofit without 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) City township governments Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) Indian/Native American Tribal Government than Federally Recognized) Regional Organization  Applications not being solicited this time.   Inquiries Please direct inquiries to: Ellen M. Werner, PhD, MA  National Heart, Lung, Blood Institute  301-435-0065  wernere@nhlbi.nih.gov 

Grant Taxonomy: